Results 371 to 380 of about 106,358 (395)
Some of the next articles are maybe not open access.
Ocular Toxicity of Hydroxychloroquine
Seminars in Ophthalmology, 2008This review summarizes the current literature regarding the ocular complications of hydroxychloroquine. Hydroxychloroquine has been used since the 1950s for the treatment of various rheumatic and dermatologic diseases. Hydroxychloroquine can cause ocular toxicity, with the most serious being an irreversible retinopathy.
Walter M. Jay +3 more
openaire +3 more sources
Current Medicinal Chemistry, 2020
Here we report on the most recent updates on experimental drugs successfully employed in the treatment of the disease caused by SARS CoV-2 coronavirus, also referred to as COVID-19 (COronaVIrus Disease 19).
M. Costanzo +2 more
semanticscholar +1 more source
Here we report on the most recent updates on experimental drugs successfully employed in the treatment of the disease caused by SARS CoV-2 coronavirus, also referred to as COVID-19 (COronaVIrus Disease 19).
M. Costanzo +2 more
semanticscholar +1 more source
Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19
Annals of Internal Medicine, 2020BACKGROUND Hydroxychloroquine and chloroquine have antiviral effects in vitro against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). PURPOSE To summarize evidence about the benefits and harms of hydroxychloroquine or chloroquine for the ...
Adrian V. Hernandez +4 more
semanticscholar +1 more source
The Treatment of Malaria with Hydroxychloroquine
The American Journal of Tropical Medicine and Hygiene, 1955Summary Two hundred and thirteen Hondurans were treated for acute malaria with hydroxychloroquine or Plaquenil® (7-chloro-4-[4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutyl-amino] quinoline diphosphate). Twenty-five of them received a single oral dose of 0.75 gram and 125 received 1.25 grams. Twenty-six others with P.
openaire +3 more sources
Hydroxychloroquine-Induced Vertigo
JAMA: The Journal of the American Medical Association, 1975SEVERE vertigo occurred in a patient receiving hydroxychloroquine sulfate in usual dosage. The reaction was confirmed by rechallenge therapy. Report of a Case A 54-year-old woman was seen at the University of Alabama in Birmingham Hospitals for chronic, destructive seronegative rheumatoid arthritis.
Joe G. Hardin, Daniel S. Prince
openaire +3 more sources
Steroids gold hydroxychloroquine
Journal of the American Academy of Dermatology, 1980Recent literature has been replete with new and innovative ideas about the pathogenesis and treatment of both common and uncommon problems encountered in the practice of dermatology . But before discussing the "new, " let us briefly turn to the " old" and examine some recent data concerning some of the most commonly used drugs in dermatology, the ...
openaire +3 more sources
Hydroxychloroquine Retinal Toxicity
New England Journal of Medicine, 2019Hydroxychloroquine Retinal Toxicity A 57-year-old woman receiving long-term hydroxychloroquine treatment presented for ophthalmic evaluation. Achromatic perimetry revealed paracentral scotomas in each eye, and optical coherence tomography revealed a loss of the retinal inner and outer segments.
Cinthia Proano, Glenn P Kimball
openaire +3 more sources
Digoxin‐Hydroxychloroquine Interaction?
Acta Medica Scandinavica, 1982ABSTRACT. Interaction between digoxin and the natural cinchona alkaloid quinidine is well documented. A possible interaction between digoxin and the semisynthetic cinchona derivative hydroxychloroquine is reported in this communication.
openaire +3 more sources
Treatment of scleromyxoedema with hydroxychloroquine
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2003Summary Background: Scleromyxoedema is a rare disease of unknown aetiology that is characterized by deposition of mucin and sclerotic induration of the skin; it is associated with paraproteinaemia. Patients suffer from progressive disability due to immobilization and cosmetic disfigurement. Treatment of scleromyxoedema is a therapeutic challenge.
Jürgen C. Becker +4 more
openaire +2 more sources
The ocular safety of hydroxychloroquine
Seminars in Arthritis and Rheumatism, 1993The insert currently supplied with hydroxychloroquine states that patients should have an initial ophthalmological assessment and then regular assessments every 3 months. The rheumatologist should expect a report from the ophthalmologist, which includes a corneal assessment of tissue dose, a reference to visual field defects if present on the Amsler ...
openaire +3 more sources